Vyome Therapeutics begins phase 2 trial of its drug for acne vulgaris
The company has dosed the first patient in its Phase 2 trial of the Company’s lead clinical candidate, VB-1953, for the treatment of moderate to severe inflammatory acne vulgaris
The company has dosed the first patient in its Phase 2 trial of the Company’s lead clinical candidate, VB-1953, for the treatment of moderate to severe inflammatory acne vulgaris